ISN-ACT Global Trials Focus: August 2019
ISN Academy. ISN-ACT . 08/13/19; 279746 Topic: Global Nephrology
Disclosure(s)(s): The ISN-Advancing Clinical Trials is a new initiative of the ISN intended to leverage existing infrastructures within ISN, in order to improve global nephrology community participation in clinical trial research. As part of its activities, the ISN-ACT highlights and sometimes analyzes important recent nephrology trials from latest medical literature every month through the ISN-ACT Trial-list. Editors of the ISN-ACT Trial-List also select clinical trials of particular impact, and collaborate with the @ISNeducation social media learning team to represent these trials visually. Join the ISN-ACT To generate more high-quality clinical trials and studies in nephrology, ISN-ACT is calling on investigators and interested individuals. If you are an ISN member interested to join this great initiative, submit your application online. Use the button below (download PDF) to download this month's edition of the list.
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Description
Discussion Forum (0)
Rate & Comment (0)
Once a month, the ISN-ACT (Advancing Clinical Trials) Global Trial Team collects and publishes a list of important nephrology trials from the latest medical literature. Each trial is reviewed in context and their risk of bias in seven key areas assessed.

This month, we reviewed the following trials:

- Rituximab superior to cyclosporine in membranous nephropathy
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy (MENTOR trial)
Fervenza, et al. N Engl J Med. 2019 Jul 4;381(1):36-46

- Amlodipine combination antihypertensive regimens best choice for first-line treatment in sub-Saharan
Africans
Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans
Ojji, et al. N Eng J Med. 2019;380:2429-39

- Dual action approach to phosphate control in CKD provides meagre results
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The
COMBINE Trial
Ix, et al. J Am Soc Nephrol. 2019;30(6):1096

- Oral GLP-1RA effective in patients with T2DM and CKD 3
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a
placebo-controlled, randomised, phase 3a trial
Mosenzon, et al. Lancet Diabetes Endocrinol 2019;7:515

- Growing evidence against treating asymptomatic bacteriuria after transplant
Antibiotic Treatment Versus No Treatment for Asymptomatic Bacteriuria in Kidney Transplant Recipients: A Multicenter
Randomized Trial
Sabe, et al. Open Forum Infect Dis. 2019;6(6):ofz243

- Lower dose alteplase sufficient to unblock occluded hemodialysis catheters
Efficacy of Alteplase 1 mg Versus 2 mg Dose in Restoring Hemodialysis Catheter Function (Alte-dose 2): A Randomized
Double-Blind Controlled Study
El-Masri, et al. Nephrology. 2019 Jul 3. doi: 10.1111/nep.13631

- All about that base: fruit and vegetable rich diet slows decline in renal function
Fruit and vegetable treatment of chronic kidney disease-related metabolic acidosis reduces cardiovascular risk better than
sodium bicarbonate
Goraya N et al. Am J Nephrol 2019;49:438-448

- Kidney transplant education to marginalized groups improves treatment options knowledge base and
capacity for informed consent
Direct delivery of kidney transplant education to black and low-income patients receiving dialysis: a randomised control trial
Waterman, et al. Am J Kidney Dis. 2019 Jun 18. pii: S0272-6386(19)30733-4

- Mycophenolate may not be as effective as oral cyclophosphamide in relapsing ANCA vasculitis
Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of
Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Randomized, Controlled Trial
Tuin, et al. Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1021-1028

- Intradialytic protein supplementation and exercise does not improve physical function or quality of life
Results from the randomized controlled IHOPE trial suggest no effects of oral protein supplementation and exercise training on physical function in hemodialysis patients
Jeong et al. Kidney Int. 2019 Apr 2. pii: S0085-2538(19)30389-8
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies